Please login to the form below

Not currently logged in

Crestor fails to outshine Lipitor

AstraZeneca's cholesterol drug Crestor has failed to show an advantage over its rival Lipitor in study data released by the pharmaceutical company

AstraZeneca's (AZ) cholesterol drug Crestor (rosuvastatin) has failed to show an advantage over its rival Lipitor (atorvastatin) in top-line study data released by the pharmaceutical company.

Results for the study's primary measure of efficacy, involving the amount of fat in a patient's arteries, demonstrated no statistically significant difference between the two treatments.

These results have the potential to damage Crestor's sales once Lipitor loses its patent protection later this year and is opened to generic completion, with healthcare providers more likely to opt for the cheaper option of two similar performing treatments.

The trial involved around 1,300 patients with coronary artery disease over a 104-week period.

Despite the failure of the primary endpoint to indicate success for Crestor, a secondary endpoint that involved an alternative process to the way fat was measured in the artery, did demonstrate a statistically significant reduction in fat build-up compared with Lipitor.

Further data and analyses will be presented by the study's academic investigators at the American Heart Association Scientific Sessions (AHA) on November 15.

5th September 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...